CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model
Globally, the accelerating spread of AI shows no sign of abating, and laws and regulations are under greater pressure to keep up. Wenpei Yu and Yunsi Hu of Lifeng Partners, together with Dr. Anja Geller of Redeker Sellner Dahs, provide an overview of the similarities and differences between the approaches taken in the EU and China, and what the future may hold
Jun Luo, Director of the Legal and Compliance Department at Shanghai SSCI Leading Fund Co., Ltd, and Taolue Zhang, Vice-Professor and Director of Tongji Intellectual Property and Competition Law Research Center at Tongji University Law School, examine the world’s first copyright infringement decision related to the platform of AI-generated content
Transfer of data across borders presents a particular compliance challenge for companies in China. Xiangxiang Ma, a partner of Anjie Broad Law Firm, analyses a new document which brings welcome practical clarification to this area
Partner Xiangxiang Ma of Anjie Broad Law Firm examines the advantages and disadvantages of two key approaches to the legal protection of vital AI algorithms
Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
2024 marked another significant year in China’s intellectual property law space. Danlei Wu of Fangda Partners examines the key developments and the indicators for further developments in the year ahead
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
